If a variant has more than one submission, it may be counted in more than one significance column. If this is the
case, the total number of variants will be less than the sum of the other cells.
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
risk factor |
total |
159
|
239
|
88
|
2
|
2
|
3
|
493
|
Gene and significance breakdown #
Total genes and gene combinations: 63
Gene or gene combination |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
risk factor |
total |
PLP1, RAB9B
|
14
|
73
|
13
|
0 |
0 |
0 |
100
|
TAFAZZIN
|
9
|
26
|
17
|
0 |
0 |
0 |
52
|
NKX2-1, SFTA3
|
18
|
24
|
1
|
0 |
0 |
0 |
43
|
MECP2
|
16
|
7
|
10
|
2
|
2
|
0 |
37
|
SMN1
|
17
|
8
|
6
|
0 |
0 |
0 |
31
|
GJC2
|
4
|
20
|
4
|
0 |
0 |
0 |
28
|
POLR3A
|
0 |
15
|
3
|
0 |
0 |
0 |
18
|
EMD
|
10
|
5
|
0 |
0 |
0 |
0 |
15
|
PTPN11
|
10
|
2
|
2
|
0 |
0 |
0 |
14
|
SLC26A4
|
4
|
3
|
4
|
0 |
0 |
0 |
11
|
BRAF
|
2
|
7
|
0 |
0 |
0 |
0 |
9
|
POLR3B
|
1
|
4
|
4
|
0 |
0 |
0 |
9
|
TUBB4A
|
1
|
8
|
0 |
0 |
0 |
0 |
9
|
CYP24A1
|
5
|
1
|
2
|
0 |
0 |
0 |
8
|
HRAS, LRRC56
|
6
|
1
|
1
|
0 |
0 |
0 |
8
|
PCNT
|
2
|
6
|
0 |
0 |
0 |
0 |
8
|
MYCN
|
4
|
2
|
0 |
0 |
0 |
0 |
6
|
TRPV4
|
2
|
3
|
1
|
0 |
0 |
0 |
6
|
CASR
|
2
|
0 |
2
|
0 |
0 |
0 |
4
|
CHRNG
|
3
|
0 |
1
|
0 |
0 |
0 |
4
|
DNASE1L1, LOC130068869, TAFAZZIN
|
0 |
4
|
0 |
0 |
0 |
0 |
4
|
HYCC1
|
0 |
4
|
0 |
0 |
0 |
0 |
4
|
LIG4
|
2
|
1
|
1
|
0 |
0 |
0 |
4
|
SOS1
|
2
|
1
|
1
|
0 |
0 |
0 |
4
|
APOL1
|
0 |
0 |
0 |
0 |
0 |
3
|
3
|
GCM2
|
3
|
0 |
0 |
0 |
0 |
0 |
3
|
MAP2K1
|
1
|
2
|
0 |
0 |
0 |
0 |
3
|
SLC16A2
|
0 |
2
|
1
|
0 |
0 |
0 |
3
|
ALMS1
|
2
|
0 |
0 |
0 |
0 |
0 |
2
|
CUBN
|
1
|
0 |
1
|
0 |
0 |
0 |
2
|
DNASE1L1, TAFAZZIN
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
DOCK6, LDLR
|
2
|
0 |
0 |
0 |
0 |
0 |
2
|
HEPACAM
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
IGHMBP2
|
0 |
0 |
2
|
0 |
0 |
0 |
2
|
KRAS
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
MLC1
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
PYGM
|
2
|
0 |
0 |
0 |
0 |
0 |
2
|
SLC2A9
|
0 |
0 |
2
|
0 |
0 |
0 |
2
|
AXDND1, NPHS2
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
COL4A5
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
COQ8B
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
CRB2
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
ITGB4
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
LDLR
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
LOC100287944, POLR3B
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
LOC123956210, SLC26A4
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
LOC126806995, MED28
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
LOC126860970, POLR3A
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
LOC126860971, POLR3A
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
MEFV
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
MIR17HG
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
MYCN, MYCNOS
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
MYH9
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
NPHS1
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
NPHS2
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
PMM2
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
PRKAR1A
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
PTPRO
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
RAF1
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
RBM10
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
SHOC2
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
SLC22A12
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
SMARCAL1
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Condition and significance breakdown #
Condition |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
risk factor |
total |
Pelizaeus-Merzbacher disease
|
14
|
73
|
13
|
0 |
0 |
0 |
100
|
not provided
|
47
|
28
|
6
|
0 |
0 |
0 |
81
|
3-Methylglutaconic aciduria type 2
|
10
|
31
|
17
|
0 |
0 |
0 |
58
|
Brain-lung-thyroid syndrome
|
17
|
23
|
1
|
0 |
0 |
0 |
41
|
Rett syndrome
|
14
|
7
|
5
|
2
|
1
|
0 |
29
|
Hypomyelinating leukodystrophy 2
|
4
|
20
|
4
|
0 |
0 |
0 |
28
|
Leukoencephalopathy, ataxia, hypodontia, hypomyelination syndrome
|
1
|
15
|
4
|
0 |
0 |
0 |
20
|
not specified
|
0 |
0 |
13
|
0 |
1
|
0 |
14
|
Pendred syndrome
|
5
|
3
|
4
|
0 |
0 |
0 |
12
|
Charcot-Marie-Tooth disease, demyelinating, IIA 1I
|
1
|
4
|
5
|
0 |
0 |
0 |
10
|
Hypomyelinating leukodystrophy 6
|
1
|
8
|
0 |
0 |
0 |
0 |
9
|
Microcephalic osteodysplastic primordial dwarfism type II
|
2
|
6
|
0 |
0 |
0 |
0 |
8
|
Feingold syndrome type 1
|
5
|
2
|
0 |
0 |
0 |
0 |
7
|
Costello syndrome
|
4
|
0 |
1
|
0 |
0 |
0 |
5
|
Focal segmental glomerulosclerosis
|
1
|
1
|
3
|
0 |
0 |
0 |
5
|
Autosomal recessive multiple pterygium syndrome
|
3
|
0 |
1
|
0 |
0 |
0 |
4
|
Hypomyelination and Congenital Cataract
|
0 |
4
|
0 |
0 |
0 |
0 |
4
|
Kugelberg-Welander disease
|
3
|
1
|
0 |
0 |
0 |
0 |
4
|
Werdnig-Hoffmann disease
|
2
|
1
|
1
|
0 |
0 |
0 |
4
|
Allan-Herndon-Dudley syndrome
|
0 |
2
|
1
|
0 |
0 |
0 |
3
|
Focal segmental glomerulosclerosis 4, susceptibility to
|
0 |
0 |
0 |
0 |
0 |
3
|
3
|
Hypercholesterolemia, familial, 1
|
2
|
1
|
0 |
0 |
0 |
0 |
3
|
X-linked Emery-Dreifuss muscular dystrophy
|
3
|
0 |
0 |
0 |
0 |
0 |
3
|
Alstrom syndrome
|
2
|
0 |
0 |
0 |
0 |
0 |
2
|
Benign hereditary chorea
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
Glycogen storage disease, type V
|
2
|
0 |
0 |
0 |
0 |
0 |
2
|
Hypercalcemia, infantile, 1
|
2
|
0 |
0 |
0 |
0 |
0 |
2
|
Hypouricemia, renal, 2
|
0 |
0 |
2
|
0 |
0 |
0 |
2
|
Megalencephalic leukoencephalopathy with subcortical cysts 1
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
Megalencephalic leukoencephalopathy with subcortical cysts 2A
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
Nephrotic syndrome, type 2
|
1
|
0 |
1
|
0 |
0 |
0 |
2
|
Spinal muscular atrophy, type II
|
1
|
0 |
1
|
0 |
0 |
0 |
2
|
Acrodysostosis 1 with or without hormone resistance
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Charcot-Marie-Tooth disease axonal type 2C
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Chronic kidney disease
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Dalmatian hypouricemia
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
Familial Mediterranean fever
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Familial hypocalciuric hypercalcemia 1
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Familial hypoparathyroidism
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Feingold syndrome type 2
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Finnish congenital nephrotic syndrome
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Focal segmental glomerulosclerosis 9
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
Metatropic dysplasia
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Nephrotic syndrome
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
Nephrotic syndrome, type 6
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
Nephrotic syndrome, type 9
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Noonan syndrome 4
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Noonan syndrome-like disorder with loose anagen hair 1
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Spinal muscular atrophy, type IV
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
Spondylometaphyseal dysplasia, Kozlowski type
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
TARP syndrome
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
X-linked Alport syndrome
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
The information on this website is not intended for direct
diagnostic use or medical decision-making without review by a
genetics professional. Individuals should not change their
health behavior solely on the basis of information contained on
this website. Neither the University of Utah nor the National
Institutes of Health independently verfies the submitted
information. If you have questions about the information
contained on this website, please see a health care
professional.